It will therefore be of significant interest to now investigate whether TPα/TPβ- mediated PRK1/2 activation can lead to further chromatin modifications in prostate cells, including recruitment of the MLL1 complex and subsequent trimethylation of H3K4, thereby leading to an altered gene expression programme in prostate tumour cells. The gene discussed is KMT2A; the disease is prostate neoplasm.